N/A
Completed N=47
Dietary Nitrate and Muscle Power With Aging
Source: ClinicalTrials.gov NCT03513302 ↗Enrolled (actual)
47
Serious AEs
0.0%
Results posted
Feb 2025
Primary outcomePrimary: Maximal Knee Extension Velocity — 12.2; 12.7 radians per second
Summary
The purpose of this study is to see if drinking beetroot juice (BRJ) is beneficial for aging patients. We hope to determine the effect of BRJ on exercise performance. BRJ improves exercise performance in athletes and normal people. We are trying to determine if BRJ improves exercise performance in aging patients. We will be comparing the effects of BRJ versus the effects of a placebo (BRJ without the nitrates that are naturally occurring in beets and other similar foods). It is thought that the benefits of BRJ may come from its natural nitrate content. Although BRJ is available for purchase in grocery stores, for the purposes of this study it is considered investigational, which means that it has not been approved as a medical therapy.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Maximal Knee Extension Velocity |
12.2; 12.7 | — |
| PRIMARY Muscle Knee Extensor Power |
3.98; 4.26 | — |
| PRIMARY Maximal Knee Extension Velocity |
12.2; 12.7 | — |
| PRIMARY Maximal Knee Extension Power |
4.23; 4.31 | — |
Eligibility Criteria
Inclusion Criteria
In good health, as determined by the investigator's review of history (provided by subject at screening visit), physical examination, and routine blood and urine tests (done at screening visit)
Exclusion Criteria
Men and women 79 years of age
- Unable to provide informed consent
- Currently pregnant or lactating (given the age range for the study, verbal confirmation by subject is believed to be sufficient)
- Current smokers
- Significant orthopedic limitations or other contraindications to strenuous exercise
- Those taking phosphodiesterase inhibitors (e.g., Viagra)
- Those taking proton pump inhibitors, antacids, xanthine oxidase inhibitors, or on hormone replacement therapy
- Those taking anti-coagulants (e.g., Coumadin) or on anti-platelet therapy
- History of neuromuscular disease (e.g., cervical spondylotic radiculomyelpathy, lumbar spondylosis, amyotrophic lateral sclerosis, Guillain-Barré syndrome, and acquired demyelinating polyneuropathies), cardiovascular disease (e.g., > stage I hypertension, heart failure, myocardial infarction/ischemia, significant myocardial or pericardial diseases (e.g. amyloidosis, constriction), moderate or severe valvular disease, renal disease, liver disease, or anemia
Data sourced from ClinicalTrials.gov (NCT03513302). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.